Oncotelic Therapeutics Chairman and CEO Vuong Trieu Reports Acquisition of $23,536.83 in Common Shares

• Oncotelic Therapeutics Chairman and CEO Vuong Trieu purchased 1,044,990 common shares at $0.017 each.
• A separate purchase comprised 312,000 common shares at $0.0185 each.
• His direct beneficial ownership rose to 95,481,309 common shares following the purchases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-049370), on October 30, 2026, and is solely responsible for the information contained therein.